摘要 |
Compounds of formula (IA) or (IB), are inhibitors of aurora kinase activity: Formula (IA), (IB) wherein -L1Y1-[CH2]z- is a linker radical wherein Y<SUP>1</SUP>, L<SUP>1</SUP> and z are as defined in the claims; R<SUB>6</SUB> is C<SUB>1</SUB>-C<SUB>4</SUB>alkoxy, hydrogen or halo; W represents a bond, -CH<SUB>2</SUB>-, -O-, -S-, -S(=O)<SUB>2</SUB>-, or -NR<SUB>5</SUB>- where R<SUB>5</SUB> is hydrogen or C<SUB>1</SUB>-C<SUB>4</SUB> alkyl; Q is =N-, =CH- or =C(X<SUP>1</SUP>)- wherein X<SUP>1</SUP> is cyano, cyclopropyl or halo; linker radicals L<SUP>2</SUP> are as defined in the claims; R is a radical of formula (X) or (Y): wherein R<SUB>1</SUB> is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R<SUB>4</SUB> is hydrogen; or optionally substituted C<SUB>1</SUB>-C<SUB>6</SUB> alkyl, C<SUB>3</SUB>-C<SUB>7</SUB> cycloalkyl, aryl, aryl(C<SUB>1</SUB>-C<SUB>6</SUB> alkyl)-, heteroaryl, heteroaryl(C<SUB>1</SUB>-C<SUB>6</SUB> alkyl)-, -(C=O)R<SUB>3</SUB>, -(C=O)OR<SUB>3</SUB>, or -(C=O)NR<SUB>3 </SUB>wherein R<SUB>3</SUB> is hydrogen or optionally substituted (C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, C<SUB>3</SUB>-C<SUB>7</SUB> cycloalkyl, aryl, aryl(C<SUB>1</SUB>-C<SUB>6</SUB> alkyl)-, heteroaryl, or heteroaryl(C<SUB>1</SUB>-C<SUB>6</SUB> alkyl)-; R<SUB>4</SUB> |
申请人 |
CHROMA THERAPEUTICS LTD;DAVIDSON, ALAN, HORNSBY;DAVIES, STEPHEN, JOHN;MOFFAT, DAVID, FESTUS, CHARLES |
发明人 |
DAVIDSON, ALAN, HORNSBY;DAVIES, STEPHEN, JOHN;MOFFAT, DAVID, FESTUS, CHARLES |